Skip to content

Burke-Hocoma Efficiency Study

Burke-Hocoma Efficiency Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03555825
Enrollment
47
Registered
2018-06-14
Start date
2016-05-01
Completion date
2020-12-31
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiparesis, Hemiplegia

Brief summary

The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.

Detailed description

In the proposed study, 20 stable subacute and chronic stroke patients will be placed in two groups: 2:1 treatment for 3 weeks (2 patients on 2 robots with one therapist; 60 minutes on robot) then 1 on 1 intervention with the therapist (60 minutes of Hocoma Armeo Spring robotic training) or visa versa. Patients will be assessed using robotic kinematics and standardized occupational therapy motor assessments. The extreme precision afforded by robotic physical rehabilitation therapies makes them an appealing and growing field in rehabilitation. Determining efficiency of new technologies, while maintaining the highest quality of care, is of priority in the medical field at this time. Devices such as the ArmeoSpring could lead to reduced disability, thereby increasing function and improving quality of life in patients experiencing neurological illness or injury. The ArmeoSpring has potential to decrease cost for both the provider and patient over time while providing more engaging, evidence-based therapy.

Interventions

DEVICEHocoma ArmeoSpring

A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.

Sponsors

Hocoma
CollaboratorUNKNOWN
Burke Medical Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Group 1: 60 minutes of Armeo treatment, 3 times per week for 6 weeks. (Half the patients will be assigned to 1:1 therapy and the other half to 2:1 therapy) Group 2: 30 minutes of Armeo treatment, 3 times per week for 6 weeks. (Half the patients will be assigned to 1:1 therapy and the other half to 2:1 therapy)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Unilateral or bilateral upper extremity hemiparesis/hemiplegia * Upper extremity Fugl-Meyer Assessment Score between 7-60 (Neither hemiplegic nor fully recovered motor function of the shoulder, elbow, wrist)

Exclusion criteria

* Inability to follow 1-2 step commands * Fixed joint contracture * Unable to tolerate repetitious movement exhibited by pain greater than 5 on Likert Scale * Any device dependent restrictions

Design outcomes

Primary

MeasureTime frameDescription
Change in Upper Extremity Fugl Meyer AssessmentBaseline, immediately after intervention, 3 month follow upImpairment measure of gross and fine motor upper extremity movements

Secondary

MeasureTime frameDescription
Patient Satisfaction Survey/Enjoyment ScaleBaseline, immediately after intervention, 3 month follow upSelf-report of experience with device and supervision; 20 question scale with 0= no satisfaction/enjoyment, 100= extremely satisfied
Box and Blocks TestBaseline, immediately after intervention, 3 month follow upTimed measure of gross manual dexterity
Grip StrengthBaseline, immediately after intervention, 3 month follow upMeasure of force generated by exerting maximal grip
Short Form Health Survey- 36Baseline, immediately after intervention, 3 month follow upSelf-report questionnaire of health status; minimum score of 0= severe disability and 100 = no disability.
Stroke Impact ScaleBaseline, immediately after intervention, 3 month follow upQuality of life measure; Consists of 59 items and assesses 8 domains; Minimum score 0= no recovery, Maximum score 100= full recovery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026